RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target

9/22/2026
Impact: 80
Healthcare

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Alkermes (NASDAQ: ALKS) while maintaining a price target of $56 for the stock. This endorsement suggests a positive outlook for the company's performance in the market.

AI summary, not financial advice

Share: